Longeveron Past Earnings Performance
Past criteria checks 0/6
Longeveron's earnings have been declining at an average annual rate of -33%, while the Biotechs industry saw earnings growing at 12.3% annually. Revenues have been declining at an average rate of 39.5% per year.
Key information
-33.0%
Earnings growth rate
-0.8%
EPS growth rate
Biotechs Industry Growth | 17.0% |
Revenue growth rate | -39.5% |
Return on equity | -317.7% |
Net Margin | -3,132.7% |
Next Earnings Update | 14 May 2024 |
Recent past performance updates
Recent updates
Will Longeveron (NASDAQ:LGVN) Spend Its Cash Wisely?
Nov 17Longeveron Inc.: A New Approach To Treat Alzheimer's
Oct 09Longeveron spikes after FDA’s Fast Track Designation for lead candidate
Aug 31Is Longeveron (NASDAQ:LGVN) In A Good Position To Invest In Growth?
Jul 15Longeveron rises ~20%, co to present Alzheimer's trial abstract at leading conference
Jul 07Longeveron: Small-Cap Biotech Targeting Large Alzheimer's Market
May 06Companies Like Longeveron (NASDAQ:LGVN) Are In A Position To Invest In Growth
Apr 03Longeveron: Speculative Biotech Worth A Look On Rare Disease, Aging, And Alzheimer's Focuses
Feb 15Longeveron: Spooky Social-Media Generated Spike Signifies Nothing
Nov 29Is Longeveron (NASDAQ:LGVN) In A Good Position To Deliver On Growth Plans?
Nov 20Revenue & Expenses BreakdownBeta
How Longeveron makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 1 | -22 | 12 | 9 |
30 Sep 23 | 1 | -21 | 11 | 10 |
30 Jun 23 | 1 | -20 | 10 | 11 |
31 Mar 23 | 1 | -20 | 9 | 11 |
31 Dec 22 | 1 | -19 | 9 | 9 |
30 Sep 22 | 1 | -18 | 10 | 8 |
30 Jun 22 | 1 | -18 | 10 | 7 |
31 Mar 22 | 1 | -17 | 11 | 7 |
31 Dec 21 | 1 | -17 | 11 | 7 |
30 Sep 21 | 2 | -14 | 9 | 7 |
30 Jun 21 | 4 | -10 | 7 | 5 |
31 Mar 21 | 4 | -7 | 4 | 4 |
31 Dec 20 | 6 | -4 | 3 | 3 |
30 Sep 20 | 6 | -3 | 3 | 2 |
31 Dec 19 | 6 | -3 | 3 | 2 |
31 Dec 18 | 2 | -6 | 3 | 4 |
Quality Earnings: LGVN is currently unprofitable.
Growing Profit Margin: LGVN is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: LGVN is unprofitable, and losses have increased over the past 5 years at a rate of 33% per year.
Accelerating Growth: Unable to compare LGVN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: LGVN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14%).
Return on Equity
High ROE: LGVN has a negative Return on Equity (-317.65%), as it is currently unprofitable.